An accurate tissue-based test 

to predict non-evolutive localized prostate cancer (LPCa)


- Use of next generation sequencing (NGS) technology for gene expression analysis

- A sensitive quantification of RNA biomarkers of interest

- A software for an accurate rendering of results


Clinical validation in 2021

Training set: preliminary results


EP18305060, 2018: Molecular signature and use thereof for the identification of indolent prostate cancer.



Kamoun A, Cancel-Tassin G, Formont g, elarouci N, et al. Comprehensive molecular classification of localized prostate adenocarcinoma reveals a tumour subtype predictive of non-aggressive disease. Annals of Oncology. 2018 August 1814-1821.